No description available.

Sea bass (Lateolabrax maculatus) has been used for dietary therapy practice in China. In traditional Chinese medicinal books, it has been indicated that sea bass can be applied for managing many inflammation associated conditions. However, the studies on the pharmacological mechanisms of anti-inflammation of sea bass remain scarce. Hence, this study aims to illustrate the pharmacological and chemical basis for the folk use of sea bass in managing inflammation- associated conditions. For in vivo studies, dietary effect of sea bass on inflammation-associated conditions in ulcerative colitis, skin wounds, and intestinal dysbiosis were evaluated. A series of inflammatory mediators associated with wound healing and ulcerative colitis, and the proliferation effects of fibroblasts upon treatments were studied via Western blotting, enzyme-linked immunosorbent assay (ELISA), hematological parameters, histopathological and Immunofluorescence analysis, using cutaneous wound model and DSS induced colitis model, respectively. β-diversity analysis and species variance statistics were conducted to evaluate the effect of ASB on the microbial communities with colitis and discovered the high dimensional biomarkers. Results showed that ASB could significantly ameliorate several pathophysiological and morphological features in DSS induced colitis. ASB has a potential in accelerating the proliferation phase of wound healing via well-organized abundant collagen deposition, angiogenesis, strengthening the skin contraction and skin organ maturation in wounds. Moreover, the study also found that ASB could significantly down-regulated the expression levels of inflammatory associated mediators in colitis and skin wound. Additionally, principal coordinate analysis (PCoA) and relative abundance at phylum level among groups were indicated that ASB possess a potential amelioration on intestinal dysbiosis in colitis. Histogram of linear discriminant analysis (LDA) scores and Cladogram as the results of LEfSe analysis identified that Christensenellaceae might be treated as the the biomarker for treating colitis. For in vivo studies, macrophages and fibroblasts were used for further evaluation. Result showed that ASB could significantly inhibited the production of pro-inflammatory mediators in lipopolysaccharide (LPS) induced macrophages. The mRNA and protein expression level of inflammatory associated mediators were significantly down-regulated upon ASB treatment. Moreover, results also suggested that ASB treatment has a closely link to accelerate the wound healing through migration and proliferation enhancement. Furthermore, the characterization of the aqueous extract of sea bass (ASB) was conducted. Six kinds of peptides and two protein identified from fraction F1 by LC-QE-HF-MS might be responsible for anti-inflammatory activity. It confirmed that Fraction F1 could be treated as the main component for contributing the potential anti-inflammatory activities to ASB. Current results illustrated that fraction F1 (kDa) is a kind of nanoparticles with stability separated from ASB. It can be treated as a promising candidate for treating inflammation associated conditions, providing the chemical basis for the folk use of sea bass in managing inflammation-associated conditions. Current studies established a pharmacological and chemical basis for the folk use of sea bass in managing inflammation-associated conditions. A further justification for the clinical application of sea bass in treating inflammation associated conditions is necessary. Keywords: sea bass; inflammation; ulcerative colitis; wound healing; gut microbiota; peptides